News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Positive Results for Peplin Inc.'s s First Phase III AK Trial



5/18/2009 12:06:08 PM

Bookmark and Share

EMERYVILLE, Calif. & BRISBANE, Australia--(BUSINESS WIRE)--Peplin, Inc. today announced positive results for PEP005 (ingenol mebutate) Gel in REGION-I, its Australian and US based Phase III actinic (solar) keratosis (AK) clinical trial for the treatment of lesions on non-head locations, which include the trunk and extremities. AK is a common pre-cancerous skin condition caused by sun exposure, which can develop into skin cancers if left untreated.


Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES